Haemonetics (HAE) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2025Income Metrics
Revenue
1.4B
Gross Profit
749.0M
55.04%
Operating Income
201.2M
14.78%
Net Income
167.7M
12.32%
Balance Sheet Metrics
Total Assets
2.5B
Total Liabilities
1.6B
Shareholders Equity
820.8M
Debt to Equity
1.99
Cash Flow Metrics
Operating Cash Flow
214.0M
Free Cash Flow
142.4M
Revenue & Profitability Trend
Haemonetics Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.4B | 1.3B | 1.2B | 993.2M | 870.5M |
| Cost of Goods Sold | 611.9M | 617.5M | 553.6M | 487.7M | 472.6M |
| Gross Profit | 749.0M | 691.5M | 615.1M | 505.5M | 397.8M |
| Operating Expenses | 499.5M | 486.2M | 426.8M | 386.9M | 308.1M |
| Operating Income | 201.2M | 173.3M | 155.7M | 71.1M | 56.9M |
| Pre-tax Income | 212.1M | 151.9M | 141.4M | 63.6M | 72.9M |
| Income Tax | 44.4M | 34.3M | 26.0M | 20.3M | -6.6M |
| Net Income | 167.7M | 117.6M | 115.4M | 43.4M | 79.5M |
| EPS (Diluted) | - | $2.29 | $2.24 | $0.84 | $1.55 |
Income Statement Trend
Haemonetics Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 935.0M | 768.9M | 769.7M | 756.0M | 693.5M |
| Non-Current Assets | 1.5B | 1.4B | 1.2B | 1.1B | 1.1B |
| Total Assets | 2.5B | 2.2B | 1.9B | 1.9B | 1.8B |
| Liabilities | |||||
| Current Liabilities | 578.1M | 300.4M | 251.8M | 442.3M | 253.5M |
| Non-Current Liabilities | 1.1B | 935.2M | 865.0M | 668.0M | 834.8M |
| Total Liabilities | 1.6B | 1.2B | 1.1B | 1.1B | 1.1B |
| Equity | |||||
| Total Shareholders Equity | 820.8M | 960.0M | 818.0M | 749.4M | 731.7M |
Balance Sheet Composition
Haemonetics Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 167.7M | 117.6M | 115.4M | 43.4M | 79.5M |
| Operating Cash Flow | 214.0M | 120.4M | 230.7M | 164.3M | 172.0M |
| Investing Activities | |||||
| Capital Expenditures | 23.3M | 1.8M | 1.6M | 2.0M | 1.8M |
| Investing Cash Flow | -105.5M | -240.5M | -33.6M | 10.2M | -388.4M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 110.7M | 30.9M | -107.4M | -22.3M | 297.2M |
| Free Cash Flow | 142.4M | 115.5M | 162.9M | 75.8M | 71.8M |
Cash Flow Trend
Haemonetics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
23.42
Forward P/E
14.52
Price to Book
4.55
Price to Sales
2.74
PEG Ratio
14.52
Profitability Ratios
Profit Margin
12.32%
Operating Margin
17.20%
Return on Equity
18.83%
Return on Assets
6.65%
Financial Health
Current Ratio
1.62
Debt to Equity
156.35
Beta
0.37
Per Share Data
EPS (TTM)
$3.31
Book Value per Share
$17.02
Revenue per Share
$27.04
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| hae | 3.7B | 23.42 | 4.55 | 18.83% | 12.32% | 156.35 |
| Abbott Laboratories | 233.3B | 17.42 | 4.78 | 30.65% | 31.89% | 27.09 |
| Boston Scientific | 154.3B | 75.79 | 6.91 | 9.50% | 11.58% | 52.16 |
| Masimo | 8.8B | 129.16 | 9.35 | -25.07% | -23.25% | 72.01 |
| Globus Medical | 7.7B | 42.44 | 1.88 | 4.63% | 7.39% | 2.27 |
| Bio-Rad | 7.1B | -3.83 | 1.03 | -27.52% | -85.16% | 20.50 |
Financial data is updated regularly. All figures are in the company's reporting currency.